Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peiyuan Tongbi is a traditional Chinese medicine (TCM) formulation used primarily for the treatment of joint diseases, particularly knee osteoarthritis. It is available in various forms such as ointment and capsules. The product is classified as an herbal medicine and has been approved for use in China since December 2017 for joint diseases. Clinical studies suggest that it may reduce joint swelling, inhibit synovial epithelial and fiber hyperplasia, decrease inflammatory cell infiltration, and alleviate articular cartilage damage. Its mechanism of action appears to involve lowering serum levels of pro-inflammatory cytokines such as IL-1 and TNF-α[1][3]. The developer and manufacturer is Shandong Province Runzhong Pharmaceutical Co., Ltd.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Peiyuan Tongbi.